| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0923d641016cff6436e693f77d90b10d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2014-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ee6159089a0f035065268f29109552 |
| publicationDate |
2019-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10266828-B2 |
| titleOfInvention |
RAS exon 2 skipping for cancer treatment |
| abstract |
There is provided SSOs targeting the region of HRAS, KRAS, and HRAS exon 2 that harbors the activating mutations and which harbors ESE activity. Moreover, there is provided SSOs targeting the 3′- and 5′-splice sites. The SSOs targeting the 5′ splice site sequence of HRAS exon 2, the 3′ splice site sequence of KRAS exon 2 and the 3′ splice site sequence of NRAS exon 2, as well as SSOs that targets ESEs in a conserved part of exon 2 in the HRAS, KRAS and NRAS exon 2 sequences can induce complete or nearly complete exon 2 skipping in cancer cell lines. This results in growth and proliferation inhibition and concomitantly in death of cancer cells. Therefore this invention is directed towards treatment of cancerous diseases and other conditions where RAS signaling is involved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023168427-A1 |
| priorityDate |
2013-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |